Neuralgia Treatment Market is driven by rising
prevalence of neuropathic pain

The neuralgia treatment market comprises drugs that are used
for the treatment of neuropathic pain caused due to peripheral nerve damage or
compression. Some of the commonly prescribed drugs in the neuralgia treatment
market include anticonvulsants, antidepressants, opioids, topical lidocaine,
and other drugs. Anticonvulsants are the primary choice of treatment due to
their effectiveness in working on voltage-gated sodium channels. The need for
neuropathic pain treatments is rising owing to the increasing prevalence of
diabetes, HIV/AIDS, shingles, and other conditions that damage the peripheral
nerves.

The global neuralgia treatment market is estimated to be
valued at USD 2.41 Bn in 2024 and is expected to reach USD
3.72 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of
6.4% from 2024 to 2031.



Key Takeaways

Key players operating in the neuralgia treatment market are GlaxoSmithKline
PLC, Pfizer Inc., Novartis AG, Biogen, Cadila Healthcare Limited, Lundbeck
Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Amgen
Inc., Eli Lilly and Company, Astellas Pharma Inc., Johnson & Johnson, Merck
& Co., Inc., AbbVie Inc., and H. Lundbeck A/S.



The growing prevalence of neuropathic pain disorders, rising geriatric population,
and increasing awareness about Neuralgia
Treatment Market Trends options are some of the key factors fueling the
demand for neuralgia treatment drugs. According to the International
Association for the Study of Pain, nearly 8% of the global population suffers
from neuropathic pain.

Get More
Insights on- Neuralgia
Treatment Market